

Long-Acting PrEP: What we learned from CROI and what we still need to know

**Sunil S Solomon, MBBS PhD MPH
Professor of Medicine and Epidemiology,
Johns Hopkins University, USA**





Disclosures

- Research grants, products and honoraria from Abbott Laboratories
- Research grants, study products and honoraria from Gilead Sciences

Long-acting Cabotegravir for PrEP

A Incident HIV Infection



The NEW ENGLAND
JOURNAL of MEDICINE

Cabotegravir for HIV Prevention
in Cisgender Men and Transgender Women

Reduction in HIV incidence compared to F/TDF:

66%


THE LANCET

Cabotegravir for the prevention of HIV-1 in women: results
from HPTN 084, a phase 3, randomised clinical trial

Reduction in HIV incidence compared to F/TDF:

88%

LA CAB in Black MSM/TG in US




What we know



LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,

The first gap in data...



Overdose Deaths Reached Record High as the Pandemic Spread

More than 100,000 Americans died from drug overdoses in the yearlong period ending in April, government researchers said.


Give this article



847



A memorial service in Baltimore last year for a man who died of an overdose.



The Journal of Infectious Diseases

SUPPLEMENT ARTICLE



Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs—United States, 2016–2019: Perspectives on Recent Experience and Lessons Learned

Sheryl B. Lyss,^{1,2} Kate Buchacz,¹ R. Paul McClung,^{1,2} Alice Asher,³ and Alexandra M. Oster^{1,2}

Other populations to remember...

- People who are incarcerated
- People with unstable housing

What we know



LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,

What we know




LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,



who were willing to be enrolled in a trial of LA CAB,


Acceptability in HPTN 083 OLE




What we don't know about acceptability



What we don't know about acceptability



So, see them then, get injected or get the shot, and go on and not worry about it for a couple months. That's awesome. That's better than taking something every day. Providence, cisgender woman



Oh, no, no, no, no, no. The only one that sticks me with needles is me and my tattoo artist. [LAUGH] Oh no, I'll stick with the pill Providence, cisgender man

How do we measure acceptability?

- Would you be willing to take an injection to prevent HIV infection?
 - And there is a very high probability you will have an injection site reaction but will resolve in about 3 days?
 - And you will need to take oral tablets for up to a year after you stop injections?
 - And there is a possibility that you might still get infected?
- **And acceptability from a provider perspective too!**

What we know



LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,



who were willing to be enrolled in a trial of LA CAB,

What we know



EFFICACY

LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,



ACCEPTABILITY

who were willing to be enrolled in a trial of LA CAB,



DELIVERY

and visit a clinical research site for their injections

Optimizing the delivery of LA CAB



What we know



EFFICACY

LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,



ACCEPTABILITY

who were willing to be enrolled in a trial of LA CAB,



DELIVERY

and visit a clinical research site for their injections

What we know



EFFICACY

LA CAB reduces incidence of HIV (compared to F/TDF) in cisgender women, cisgender men who have sex with men and transwomen at risk of HIV from sexual intercourse,



ACCEPTABILITY

who were willing to be enrolled in a trial of LA CAB,



DELIVERY

and visit a clinical research site for their injections



COST

Whether or not LA CAB is cost-saving depends on the pricing of LA CAB vs. generic F/TDF


What we know

- Can it be cost saving?

“....we found that at a range of costs, CAB-LA for PrEP provides good value for money if its annual price is less than \$50 000 to \$300 000 per person per year.”



“.... The cost per CAB-LA injection is \$8.99/injection (high coverage; minimum duration 2 months) compared with the cost of a 2-month supply of TDF/FTC to remain on treatment (\$8.99/injection (high coverage; minimum duration 2 months)).”



“....we found that at a range of costs, CAB-LA for PrEP provides good value for money if its annual price is less than \$50 000 to \$300 000 per person per year.”



“.... The cost per CAB-LA injection is \$8.99/injection (high coverage; minimum duration 2 months) compared with the cost of a 2-month supply of TDF/FTC to remain on treatment (\$8.99/injection (high coverage; minimum duration 2 months)).”

What we still need to know...

Marrazzo #163


Adherence??



Duration of use?

Adherence and HIV incidence in 6000 women

Cross-sectional Objective and Subjective Adherence by Visit (n = 2955)




- By both measures, overall adherence decreased over time
- Higher adherence reported with subjective measures

DBS, dried blood spot; ECM, electronic pill cap-monitoring; PC, pill-counts; SR, self-report
CROI; February 19-22, 2023; Seattle, Washington

Longitudinal Patterns of Adherence By Group-based Trajectory


HIV Incidence Rates Among Women with Available Adherence Data (n = 2955)



- Even with low incidence overall, higher patterns of adherence were directly associated with lower risk of HIV acquisition

Calculated by Poisson regression.

CROI; February 19-22, 2023; Seattle, Washington



What we still need to know...

Marrazzo #163

Adherence??

Kakande #124; Kanya #128

2+1+1

q6m

*Molina #119;
Stewart #121*

doxyPEP

q2m

So, see them then, get injected or get the shot, and go on and not worry about it for a couple months. That's awesome. That's better than taking something every day. Providence, cisgender woman

Oh, no, no, no, no, no. The only one that sticks me with needles is me and my tattoo artist. [LAUGH] Oh no, I'll stick with the pill Providence, cisgender man


Riddler #164

Grattoni #165

Duration of use?

? q2y

Where does LA CAB fit in?



Acknowledgements

- People who graciously participate in research studies globally